Interaction of the Atypical Tetracyclines Chelocardin and Amidochelocardin with Renal Drug Transporters-Reference-Cited by-同舟云学术

Interaction of the Atypical Tetracyclines Chelocardin and Amidochelocardin with Renal Drug Transporters

Published:2024-06-11 Issue:7 Volume:7 Page:2093-2109
ISSN:2575-9108
Container-title:ACS Pharmacology & Translational Science
language:en
Short-container-title:ACS Pharmacol. Transl. Sci.

Author:

Rox Katharina¹²^ORCID,Kühne Annett³,Herrmann Jennifer²⁴^ORCID,Jansen Rolf⁵,Hüttel Stephan²⁵,Bernecker Steffen⁵,Hagos Yohannes³,Brönstrup Mark¹²^ORCID,Stadler Marc²⁵^ORCID,Hesterkamp Thomas²⁶,Müller Rolf²⁴^ORCID

Affiliation:

1. Department of Chemical Biology, Helmholtz Centre for Infection Research (HZI), 38124 Braunschweig, Germany

2. German Center for Infection Research (DZIF), partner site Braunschweig-Hannover, 38124 Braunschweig, Germany

3. PortaCellTec Biosciences GmbH, 37079 Göttingen, Germany

4. Department of Microbial Natural Products, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) and Department of Pharmacy, Saarland University, 66123 Saarbrücken, Germany

5. Department of Microbial Drugs, Helmholtz Centre for Infection Research (HZI), 38124 Braunschweig, Germany

6. Translational Product Management Office, German Center for Infection Research (DZIF), partner site Braunschweig-Hannover, 38124 Braunschweig, Germany

Funder

Deutsches Zentrum f??r Infektionsforschung

Helmholtz Centre for Infection Research

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acsptsci.4c00183

Reference64 articles.

1. The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System

2. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis

3. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019

4. Towards the sustainable discovery and development of new antibiotics

5. Fighting antibiotic resistance—strategies and (pre)clinical developments to find new antibacterials